Description of Company and Basis of Presentation (Details) $ / shares in Units, shares in Millions, $ in Millions		9 Months Ended
	Jul. 27, 2017 USD ($) $ / shares shares	Sep. 30, 2017 Class Drug Candidate Patient
Description of Company and Basis of Presentation [Abstract]
Number of classes of ultra-high potency drug conjugates | Class		2
Number of designed drug conjugates with highly potent cytotoxic payloads | Drug		75
Number of distinct classes of compound | Class		2
Number of lead candidates | Candidate		4
Number of patients tested for various types of cancer | Patient		600
Number of years Orphan Drug Designation provides several benefits of market exclusivity after approval		7 years
Number of years soft tissue sarcomas confers market among other benefits		10 years
Schedule of Strategic Investment Agreement [Line Items]
Reserve stock split		6
NantCell, Inc [Member]
Schedule of Strategic Investment Agreement [Line Items]
Net proceeds received from the sale of common stock | $	$ 13
Common stock, share price (in dollars per share) | $ / shares	$ 6.60
Percentage of common stock premium at market price	92.00%
Warrants to purchase shares of common stock (in shares) | shares	0.5
Warrants exercise price (in dollars per share) | $ / shares	$ 6.60
Period to purchase common stock by exercising warrants	18 months
NantCell, Inc [Member] | Maximum [Member]
Schedule of Strategic Investment Agreement [Line Items]
Fee contingent payments entitled to be received under license agreement | $	$ 343